The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2023 | SKylaRk trial update: Isa-KRd in newly diagnosed, transplant-eligible multiple myeloma
In this video, Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses findings from the SKylaRk trial (NCT04430894), which is evaluating the safety and efficacy of isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in patients with transplant-eligible, newly diagnosed multiple myeloma (NDMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
